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Abstract
Introduction: Treatment of severe hemorrhagic shock due to acute blood loss from traumatic injuries in a Jehovah’s witness (JW)
trauma patient is very challenging since hemostatic blood product resuscitation is limited by refusal of the transfusion of allogeneic
blood products.
Case Presentation: We describe a multifaceted approach to the clinical care of a severely anemic JW trauma patient including
the early administration of a bovine hemoglobin-based oxygen carrier (HBOC) as a bridge to resolution of critical anemia (nadir
hemoglobin 3.9 g/dL). Hemoglobin-based oxygen carrier infusions were used to supplement oxygen delivery until endogenous ery-
thropoiesis could restore adequate red blood cell mass. Subsequent endogenous bone marrow recovery was supported by early
administration of high-dose erythropoiesis-stimulating agents and iron supplementation.
Conclusions: Early HBOC administration can be used in the treatment of severe hemorrhagic shock in trauma patients who refuse
allogeneic blood.
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1. Introduction
Hemorrhage is the leading cause of preventable death
in the early phase of trauma. Prevention of death from
hemorrhage requires rapid hemorrhage control and ap-
propriate hemostatic resuscitation. In Jehovah’s witness
(JW) patients with severe traumatic injuries, hemostatic re-
suscitation is limited by refusal of the transfusion of allo-
geneic blood products.
Nontraditional methods of reducing blood loss and
optimizing erythropoiesis have been used to support ane-
mic JW patients including exogenous erythropoietin ad-
ministration, folic acid, ascorbic acid and iron supplemen-
tation (1, 2). Using these methods, survival has been re-
ported following high volume blood loss in JW patients in-
cluding ruptured aortic dissection (3), splenic laceration
(4), poly-trauma (5, 6) and subtotal colectomy for bleed-
ing (7). However, death following surgical interventions
for traumatic injuries in JW patients has also been reported
(8, 9).
To prevent both ischemic complications and death due
to critical anemia and lack of oxygen delivery, hemoglobin-
based oxygen carriers (HBOC) have been used to supple-
ment oxygen delivery until endogenous erythropoiesis
can restore adequate red blood cell mass (10, 11).This case
report describes a multifaceted approach to care of a
severely anemic JW trauma patient including the adminis-
tration of a bovine HBOC as a bridge to resolution of critical
anemia with endogenous bone marrow recovery.
2. Case Presentation
A 23-year-old male pedestrian was struck and crushed
between two cars. In the trauma bay he had an intact air-
way, clear breath sounds, normal mentation, heart rate 99
and systolic blood pressure 118/65 mmHg. Physical exam
confirmed diffuse abdominal tenderness, severe pelvic
tenderness and right flank and left lower back contusions.
He complained of abdominal, back and right groin pain.
Admission hemoglobin was 13.4 g/dL (hematocrit 42.8%).
CT scan of the abdomen/pelvis revealed a Grade III
liver laceration in the posterior segment of the right hep-
atic lobe, extending to the right hepatic and portal veins,
with associated hemoperitoneum (Figure 1 A) and a pelvic
hematoma with active hemorrhage in the space of Retz-
ius and periurethral region (Figure 1 B). Angiography con-
firmed segmental extravasation from branches of both
right and left internal iliac arteries and bleeding from
branches of the right hepatic artery which required selec-
tive embolization. An inferior vena cava filter was placed.
Repeat hematocrit following angiography was 15.1%
and decreased further to 11.7% (hemoglobin 3.9 g/dL). Co-
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Figure 1. A, CT scan of the abdomen/pelvis confirming a Grade III liver laceration in the posterior segment of the right hepatic lobe, extending to the right hepatic vein
and portal system, Associated hemoperitoneum is noted; B, CT scan of the abdomen/pelvis confirming a severe open-book pelvic fracture with pelvic hematoma with active
hemorrhage in the space of Retzius and peri-urethral region.
agulation profile was normal. He developed worsening
tachycardia and hypotension. Both patient and family de-
clined allogeneic red blood cell (RBC) transfusion. Com-
passionate use Hemopure (3 units/90 g hemoglobin/250
mL, HBOC-201 bovine Hb glutamer-250, OPK Biotech, Cam-
bridge, MA) was administered via FDA compassionate use
program approximately 30 hours after admission. Daily
high-dose recombinant erythropoietin and IV iron su-
crose were initiated. Additional Hemopure transfusions (4
units) were administered over the next 6 days (Figure 2).
Figure 2. Hematocrit Cellular Hemoglobin and Free Hemoglobin Levels During the
JW Trauma Patient’s Hospital Course
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Hemopure administration is represented by the free hemoglobin level.
Phlebotomy was minimized with pediatric tube use.
When hematocrit was stable (24%) on post-trauma day 12,
he underwent surgery for percutaneous pinning of pelvic
fractures. He was discharged home the next day with out-
patient physical therapy with hemoglobin 7.7 g/dL (hema-
tocrit 25.5%). Renal function was unchanged by Hemopure
administration (total 7 units transfused) as serum creati-
nine did not rise above 1.0 mg/dL throughout his hospital
course.
3. Discussion
This case highlights several important features of
trauma management of a JW patient who refuses transfu-
sion of allogeneic blood. First, HBOCs can temporarily sup-
ply enough hemoglobin to support oxygen delivery in the
patient with critical anemia. Second, endogenous produc-
tion of erythrocytes can be facilitated by exogenous ery-
thropoietin and iron supplementation. Third, the combi-
nation of a HBOC, erythropoietin and iron can enhance
hemoglobin levels over several days in preparation for safe,
non-emergent surgery. Finally, it is critical to minimize un-
necessary iatrogenic diagnostic blood loss that may exac-
erbate anemia.
HBOCs, developed via polymerization or human or
bovine hemoglobin (12), are not approved by the FDA (re-
quire compassionate use approval) (13), but are approved
for human clinical use in South Africa and Russia. Most
JW patients will accept Hemopure (derived from bovine
hemoglobin). HBOCs underwent multiple clinical trials
and were not FDA-approved due to higher rates of myocar-
dial infarction and death most likely related to hyperten-
sion and vasoconstriction from the nitric oxide scaveng-
ing properties of free hemoglobin, but this meta-analysis
was flawed in that it included multiple HBOC products (14).
HBOC-201 eliminated allogeneic transfusion in the major-
ity of subjects in a multicenter Phase III trial in elective
orthopedic surgery (15). Although HBOCs have failed to
show significant benefit over allogeneic human RBC trans-
fusion, this case highlights a scenario in which allogeneic
RBC transfusion is not an option and HBOCs are an accept-
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able alternative, similar to potential use in military or rural
areas where RBC transfusion is not available.
The optimal hemoglobin level at which to consider
HBOC administration is unclear, but 5 - 6 g/dL is com-
monly used. Increased mortality has been documented
with hemoglobin less than 5 g/dL (16, 17) and the odds ra-
tio for death in patients who refuse blood transfusion in-
creases 2.5 for every 1 g less than 8 g/dL (18). In a prior study
of HBOC use in trauma, myocardial ischemia as evidence
by ST changes on electrocardiogram and elevated troponin
levels developed when hemoglobin decreased below 4 g/dL
(10) at which time HBOCs were transfused. The long-term
cognitive effects of critical anemia are unclear. Therefore,
consideration for HBOC administration should occur once
hemoglobin is 5 - 6 g/dL.
Immobilized trauma patients have a high rate of deep
vein thrombosis. High dose erythropoietin may further in-
crease thrombotic risk in trauma patients (19, 20). This pa-
tient pre-emptively had an IVC filter placed during angiog-
raphy which should be considered in similar patients.
In conclusion, this case demonstrates that a multi-
faceted approach to hemorrhagic shock management in a
trauma patient who refuses allogeneic blood transfusion
can ensure adequate oxygen delivery with concomitant
early administration of HBOCs for acute blood loss and
erythropoietin and iron to augment endogenous erythro-
poiesis.
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